ReviewCancer journal (Sudbury, Mass.)
BRAF-Directed Therapy in Metastatic Colorectal Cancer.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04028479 (The Registry of Oncology Outcomes Associated With Testing and Treatment), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Targeting molecular and genetic pathways driving tumorigenesis for precision therapy in colorectal cancer.Cancer biology & therapy · 2026Review
- Integrated molecular profiling ofJournal of gastrointestinal oncology · 2024Article
- Predictive Genetic Biomarkers for the Development of Peritoneal Metastases in Colorectal Cancer.International journal of molecular sciences · 2023Article
- Genomic Landscape of Actionable Mutations in Primary and Metastatic Tissues of Colon Adenocarcinoma.Cureus · 2022Article
- High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma.Journal of computer-aided molecular design · 2021Article
- Early response in phosphorylation of ribosomal protein S6 is associated with sensitivity to trametinib in colorectal cancer cells.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Mutational Characterization of Colorectal Cancer from Korean Patients with Targeted Sequencing.Journal of Cancer · 2021Article
- Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAFFrontiers in pharmacology · 2021Article
- Article
- Article
- Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.Annals of surgical oncology · 2020Article
- Mps1 is associated with the BRAFOncology letters · 2019Article
- Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.British journal of cancer · 2019Article
- Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases.Diagnostic pathology · 2018Article
- How to find the right drug for each patient? Advances and challenges in pharmacogenomics.Current opinion in systems biology · 2018Review
- Update on Sporadic Colorectal Cancer Genetics.Clinics in colon and rectal surgery · 2018Review
- AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status.British journal of cancer · 2018Article
- Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.Expert opinion on investigational drugs · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Activating BRAF (V-raf murine sarcoma viral oncogene homolog B) mutations occur in approximately 5% to 10% of patients with metastatic colorectal cancer, mostly V600E mutation, and it is associated with distinct clinical and pathological features. To date, there are no approved treatments to target this mutation. BRAF inhibitor monotherapy has limited efficacy, in contrast to metastatic melanoma. Combination strategies that block not only BRAF mutated kinase but other alternative pathways are ongoing and have demonstrated improved activity. This review aims to provide data about new strategies to target to BRAF gene mutation in metastatic colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.